The companion animal veterinary vaccines market consists of sales of companion animal vaccines by entities (organizations, sole traders and partnerships) that manufacture companion animal vaccines. Companion animal vaccines are substances that are used to stimulate the production of antibodies and provide immunity against one or several diseases in pets such as dogs, birds and cats. Only goods and services traded between entities or sold to end consumers are included.
The global companion animal veterinary vaccines market is expected to decline from $2.72 billion in 2019 to $2.60 billion in 2020 at a compound annual growth rate (CAGR) of -4.34%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $3.22 billion in 2023 at a CAGR of 7.43%.